Adaptive Biotechnologies Raises Fiscal 2026 Revenue Guidance on Nov. 4
The company now expects fiscal 2026 revenue of $276 million to $286 million. Related Stocks: ADPT ,
The company now expects fiscal 2026 revenue of $276 million to $286 million. Related Stocks: ADPT ,